ENVB
What one share of Enveric Biosciences holds
Pharmaceutical Preparations
We are a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, we are advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects.
Enveric Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.40 |
|---|---|
| Cash and investments | $2.11 |
| Book value | $2.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$1,555 | $6.02 | −$369.88 | — | $513.24 |
| 2022 | — | −$195.02 | $6.06 | −$183.93 | — | $105.90 |
| 2023 | — | −$121.29 | $0.04 | −$97.96 | — | $10.71 |
| 2024 | — | −$228.48 | — | −$184.36 | — | $28.19 |
| 2025 | — | −$36.24 | — | −$24.32 | — | $3.94 |